242 related articles for article (PubMed ID: 20839029)
41. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
42. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
43. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
[TBL] [Abstract][Full Text] [Related]
44. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
45. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
Mross K; Scheulen ME; Licht T; Unger C; Richly H; Stern AC; Kutz K; Camboni MG; Barbieri P; Verdi E; Vincenzi B; Bernareggi A
Anticancer Drugs; 2004 Jan; 15(1):15-22. PubMed ID: 15090738
[TBL] [Abstract][Full Text] [Related]
46. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
Ewesuedo RB; Iyer L; Das S; Koenig A; Mani S; Vogelzang NJ; Schilsky RL; Brenckman W; Ratain MJ
J Clin Oncol; 2001 Apr; 19(7):2084-90. PubMed ID: 11283142
[TBL] [Abstract][Full Text] [Related]
47. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
[TBL] [Abstract][Full Text] [Related]
48. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hidalgo M; Siu LL; Nemunaitis J; Rizzo J; Hammond LA; Takimoto C; Eckhardt SG; Tolcher A; Britten CD; Denis L; Ferrante K; Von Hoff DD; Silberman S; Rowinsky EK
J Clin Oncol; 2001 Jul; 19(13):3267-79. PubMed ID: 11432895
[TBL] [Abstract][Full Text] [Related]
49. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
50. Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.
Schöffski P; Dumez H; Ruijter R; Miguel-Lillo B; Soto-Matos A; Alfaro V; Giaccone G
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1397-403. PubMed ID: 21465314
[TBL] [Abstract][Full Text] [Related]
51. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
52. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
53. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
Isambert N; Delord JP; Soria JC; Hollebecque A; Gomez-Roca C; Purcea D; Rouits E; Belli R; Fumoleau P
Ann Oncol; 2015 May; 26(5):1005-1011. PubMed ID: 25646368
[TBL] [Abstract][Full Text] [Related]
54. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
55. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
56. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
57. Phase I clinical trial of continuous infusion cyclopentenyl cytosine.
Politi PM; Xie F; Dahut W; Ford H; Kelley JA; Bastian A; Setser A; Allegra CJ; Chen AP; Hamilton JM
Cancer Chemother Pharmacol; 1995; 36(6):513-23. PubMed ID: 7554044
[TBL] [Abstract][Full Text] [Related]
58. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
59. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
[TBL] [Abstract][Full Text] [Related]
60. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
